MARKET

MNKD

MNKD

MannKind
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.660
+0.030
+1.84%
Closed 19:48 08/04 EDT
OPEN
1.640
PREV CLOSE
1.630
HIGH
1.660
LOW
1.600
VOLUME
1.23M
TURNOVER
--
52 WEEK HIGH
2.480
52 WEEK LOW
0.8000
MARKET CAP
353.81M
P/E (TTM)
-7.2017
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MNKD stock price target is 3.000 with a high estimate of 4.000 and a low estimate of 2.500.

EPS

MNKD News

More
MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020
GlobeNewswire · 6d ago
MannKind (MNKD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zacks · 6d ago
Alejandro Galindo Joins MannKind as Chief Commercial Officer
GlobeNewswire · 07/20 14:00
Alejandro Galindo Joins MannKind As Chief Commercial Officer
Benzinga · 07/20 13:04
MannKind (MNKD) Presents At Lytham Partners Virtual Investor Growth Conference - Slideshow
Seeking Alpha - Article · 06/26 17:37
MannKind Corporation (MNKD) CEO Michael Castagna Presents at Lytham Partners Virtual Investor Growth Conference (Transcript)
Seeking Alpha - Transcript · 06/24 20:25
MNKD, HTZ, WKHS and NBR among midday movers
Seeking Alpha - Article · 06/24 16:42
MannKind (MNKD) Looks Good: Stock Adds 5.5% in Session
Zacks · 06/22 13:30

Industry

Biotechnology & Medical Research
+0.02%
Pharmaceuticals & Medical Research
-0.36%

Hot Stocks

Symbol
Price
%Change

About MNKD

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
More

Webull offers kinds of MannKind Corporation stock information, including NASDAQ:MNKD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNKD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MNKD stock methods without spending real money on the virtual paper trading platform.